Positive News SentimentPositive NewsNASDAQ:TIL Instil Bio (TIL) Stock Price, News & Analysis $21.89 +0.17 (+0.78%) (As of 12/24/2024 04:20 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Instil Bio Stock (NASDAQ:TIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Instil Bio alerts:Sign Up Key Stats Today's Range$20.70▼$21.9050-Day Range$19.60▼$41.0052-Week Range$7.10▼$92.00Volume56,285 shsAverage Volume102,017 shsMarket Capitalization$142.85 millionP/E RatioN/ADividend YieldN/APrice Target$145.00Consensus RatingModerate Buy Company OverviewInstil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Read More… Instil Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks71st Percentile Overall ScoreTIL MarketRank™: Instil Bio scored higher than 71% of companies evaluated by MarketBeat, and ranked 306th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingInstil Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInstil Bio has only been the subject of 2 research reports in the past 90 days.Read more about Instil Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Instil Bio are expected to grow in the coming year, from ($10.61) to ($8.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Instil Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Instil Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInstil Bio has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.02% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Instil Bio has recently decreased by 19.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInstil Bio does not currently pay a dividend.Dividend GrowthInstil Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.02% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Instil Bio has recently decreased by 19.59%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News SentimentN/A News SentimentInstil Bio has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Instil Bio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for TIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Instil Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Instil Bio insiders have not sold or bought any company stock.Percentage Held by Insiders46.50% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Instil Bio's insider trading history. Receive TIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TIL Stock News HeadlinesInstil Bio Secures Loan to Refinance FacilityDecember 23 at 5:35 PM | tipranks.comCautious Hold Rating for Zura Bio Amid Efficacy Concerns and Licensing ChallengesNovember 18, 2024 | markets.businessinsider.comMysterious drone activity triggers massive 1,366% surgeIf mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.December 25, 2024 | Insiders Exposed (Ad)Strategic Acquisitions and Market Potential Position Instil Bio’s SYN-2510 as a Buy with High Growth ProspectsNovember 18, 2024 | markets.businessinsider.comInstil Bio price target lowered to $110 from $120 at H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comInstil Bio Poised for Growth Amid Biopharmaceutical Sector Activity and Strong Financial PositionNovember 15, 2024 | markets.businessinsider.comMerck to buy rights to Chinese cancer drug for up to $3.3BNovember 14, 2024 | msn.comInstil Bio (TIL) Gets a Hold from JMP SecuritiesNovember 14, 2024 | markets.businessinsider.comSee More Headlines TIL Stock Analysis - Frequently Asked Questions How have TIL shares performed this year? Instil Bio's stock was trading at $7.62 at the start of the year. Since then, TIL stock has increased by 187.3% and is now trading at $21.89. View the best growth stocks for 2024 here. How were Instil Bio's earnings last quarter? Instil Bio, Inc. (NASDAQ:TIL) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($2.29) EPS for the quarter, topping analysts' consensus estimates of ($2.98) by $0.69. When did Instil Bio's stock split? Instil Bio shares reverse split on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Instil Bio IPO? Instil Bio (TIL) raised $250 million in an initial public offering on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities served as the underwriters for the IPO. Who are Instil Bio's major shareholders? Top institutional investors of Instil Bio include BML Capital Management LLC (5.15%), Point72 Asset Management L.P. (1.47%), Geode Capital Management LLC (0.62%) and Fred Alger Management LLC (0.48%). View institutional ownership trends. How do I buy shares of Instil Bio? Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Instil Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Instil Bio investors own include Tesla (TSLA), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Taysha Gene Therapies (TSHA), Viking Therapeutics (VKTX), Golden Minerals (AUMN) and Walt Disney (DIS). Company Calendar Last Earnings8/13/2024Today12/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TIL CUSIPN/A CIK1625584 Webwww.tillcap.com Phone972-499-3350FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$145.00 High Stock Price Target$180.00 Low Stock Price Target$110.00 Potential Upside/Downside+562.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($11.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-156,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.44% Return on Assets-25.08% Debt Debt-to-Equity Ratio0.47 Current Ratio12.90 Quick Ratio12.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$34.72 per share Price / Book0.63Miscellaneous Outstanding Shares6,526,000Free Float3,491,000Market Cap$142.85 million OptionableNo Data Beta1.61 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:TIL) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.